Monoclonal Humanized One-Armed Antibody Blocking Therapy ... - Neurology
2023年4月25日 · ANRE pathogenic autoantibodies (autoAbs) bind to limited epitopes in the N-terminal domain (NTD) of NMDA-NR1, cross link NMDAR, and induce receptor internalization leading to hypofunction of NMDAR. We engineered a non-pathogenic recombinant one-armed humanized IgG (ART5803) which binds to the NTD epitope of NMDAR-NR1.
Peripherally Administered Therapeutic One-armed Antibody …
2024年4月9日 · ANRE pathogenic autoantibodies (autoAbs) bind to limited epitopes in the N-terminal domain (NTD) of NMDAR NR1 subunit, crosslink NMDARs, induce receptor internalization and associated neurological symptoms. We engineered a one-armed IgG (ART5803) to bind with high affinity to the NTD of NMDAR-NR1 …
MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits …
2008年6月2日 · We have developed MetMAb, a monovalent monoclonal antibody (mAb) against c-Met, which blocks HGF binding to c-Met and subsequent pathway activation. MetMAb and other anti-HGF antibodies have shown potent activity in the U-87 MG autocrine glioblastoma tumor model (27 – 29); however, it had previously not been evaluated in pancreatic cancer models.
Next generation antibody drugs: pursuit of the 'high-hanging …
2017年12月1日 · Proliferative signals have been avoided by monovalent engagement of MET with an engineered one-armed antibody 124 or, alternatively, by using an unusual antibody that binds in a unique manner...
hOA-DN30: a highly effective humanized single-arm MET antibody …
2022年3月29日 · Here we describe the design and validation of the DN30 mAb humanized one-arm form (hOA-DN30), and present data demonstrating its robust anti-proliferative and tumor growth-inhibitory effects in multiple MET-addicted cell lines and xenograft cancer models, as well as its favorable pharmacokinetics and safety profile in non-human primates.
SHR-A1403, a novel c-Met antibody-drug conjugate, exerts
2019年1月14日 · Here we described both the in vitro and in vivo efficacies of SHR-A1403, a novel c-Met ADC composed of a humanized IgG2 monoclonal antibody against c-Met conjugated to a novel cytotoxic...
Abstract Details - American Academy of Neurology
ANRE pathogenic autoantibodies (autoAbs) bind to limited epitopes in the N-terminal domain (NTD) of NMDA-NR1, crosslink NMDAR, and induce receptor internalization leading to hypofunction of NMDAR. We engineered a non-pathogenic recombinant one-armed humanized IgG (ART5803) which binds to the NTD epitope of NMDAR-NR1.
Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor ...
2019年8月5日 · A one-armed anti-c-Met antibody, derived from a full-length antibody whose epitope overlapped with the HGF-binding site, was designed to antagonize the HGF/c-Met signaling axis by blocking the HGF/c-Met interaction. 2E6 was first tested for its ability to compete with HGF in a ligand-binding assay.
Progress of antibody–drug conjugates (ADCs) targeting c
2024年4月10日 · Therefore, development of therapeutic antibody targeting c-Met has predominantly centered on the use of “one-armed” antibody (aonartuzumb) or anti-HGF antibody (rilotumumab) [49,50,51], demonstrating greater promise due to the absence of agonistic activity.
One-armed 5D5 (OA5D5) is a potent humanized HGF-blocking …
2007年5月1日 · One-armed 5D5 (OA5D5) is a potent humanized HGF-blocking anti-c-Met monovalent antibody that inhibits HGF-dependent activity in vitro and demonstrates anti-tumor efficacy in vivo